Synthetic data only. Never enter patient information; nothing is sent or stored. For clinicians. Not FDA cleared.For licensed clinicians. Educational demonstration on synthetic data. Never enter real patient identifiers or protected health information: everything runs in your browser and nothing is sent or stored. Clinical decision support only; not FDA cleared; physician review is required.
CPE-003 · synthetic case CKD-EX-11
eGFR fell 35% after a kidney-protective drug
A hemodynamically active therapy was started; eGFR dropped 35%.
Purpose: A hemodynamically active therapy was started; eGFR dropped 35%.
Inputs the engine received
Patient
- Age
- 64 years
Context
- Sex for equation
- male
- CKD confirmed
- Yes
- G category
- G3a
- Hemodynamically active therapy recently initiated or increased
- Yes
Laboratory
- Percent change eGFR from pretherapy
- -35 %
What the engine reports
Detected clinical pattern
CKD Criteria Met — Classification Incomplete
Chronicity is documented, but the A category (UACR) is missing, so risk classification is incomplete.
- Chronicity: Chronicity confirmed (≥3 months)
Clinical summary
CKD criteria met on documented chronicity (); classification is incomplete without UACR. Physician adjudication required.
Missing information
- UACR (required for the A category and risk assessment).
- UACR (required for the A category, risk assessment and a complete classification).
Why it matters
The result is placed in context so the physician can see what is established, what is provisional and what is missing.
Progression signal: therapy associated eGFR decline requires evaluation.
Evidence and rule trace · 3 rules
CGA-001Assign G category from selected indexed eGFR
Inputs: G category G3a (documented)
G3a (45–59 mL/min/1.73 m²)
CGA-005Incomplete classification when UACR absent
Inputs: G3a · UACR missing
confirmed_ckd_incomplete_risk_classification
PROG-002Hemodynamically active therapy eGFR change
Inputs: eGFR change -35% after hemodynamically active therapy
therapy_associated_eGFR_decline_requires_evaluation: do not automatically discontinue kidney-protective therapy
Evidence
- R1 · KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Disease: Improving Global Outcomes (KDIGO), 2024.
Physician adjudication required. Clinical decision support for physician review. Criteria-based status is not a probability. Findings require physician adjudication and correlation with the complete clinical context. Validation-only release: not for production clinical use.
Change the values
The same engine, starting from this case. Change any value and watch the pattern and the rule trace react.
Live eGFR and CGA map
eGFR (mL/min/1.73 m²)
—
enter a creatinine
| GFR \ ALB | A1<30 | A230–300 | A3>300 |
|---|---|---|---|
| G1≥90 | |||
| G260–89 | |||
| G3a45–59 | |||
| G3b30–44 | |||
| G415–29 | |||
| G5<15 |
No cell is shown until there are data. Colors follow the KDIGO risk heat map: green low, yellow moderately increased, orange high, red very high.
Kidney functionAdd a prior result with dates to test chronicity
Switches the engine to the combined eGFRcr-cys equation.
Albuminuria
Chemistry
Kidney findings and red flags
Context
Transient albuminuria confounders
Creatinine may be unreliable
Complications (persistent)
Therapy
Documented history and special populations
This case also carries values that have no field here: G_category, hemodynamically_active_therapy_recently_initiated_or_increased, percent_change_eGFR_from_pretherapy. They are included in the calculation until you clear the form.
More kidney cases
CKD-FX-001
Persistent moderately increased albuminuria with preserved GFR
Persistent moderately increased albuminuria with preserved GFR
CKD-FX-002
Persistent severely increased albuminuria with mildly decreased GFR
Persistent severely increased albuminuria with mildly decreased GFR
CKD-FX-003
Single reduced eGFR without chronicity
Single reduced eGFR without chronicity
CKD-FX-004
Acute creatinine rise before CKD staging
Acute creatinine rise before CKD staging
CKD-FX-005
Isolated suspected G3a requiring cystatin C confirmation support
Isolated suspected G3a requiring cystatin C confirmation support
CKD-FX-006
Combined eGFR reclassification support
Combined eGFR reclassification support
Try Biod in your practice
The Clinical Intelligence Layer — transforming fragmented clinical information into structured intelligence for clinician review and action.